

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)
2. (Currently Amended) A method of identifying a drug candidate compound ~~useful~~ for the treatment of an angiogenesis mediated disorder, comprising the steps of:
 - a. using a three-dimensional (3D) structure of an HPTPbeta catalytic domain as defined by the atomic coordinates of Figures 7-102; 103-201; 202-252; and 253-304; or combination thereof; and
 - b. employing said 3D structure to design, modify, or select a compound that binds HPTPbeta *in silico*.
3. (Cancelled)
4. (Cancelled)
5. (Currently Amended) A method of identifying a drug candidate compound ~~useful~~ for the treatment of an angiogenesis mediated disorder, comprising the steps of:
 - a. selecting compounds based on computer-aided drug design (CADD) using the structural coordinates described in Figures 7-304;
 - b. analyzing if the compound, binds or modulates HPTPbeta in an *in vitro*, *in vivo*, or *ex vivo* assay; and
 - c. identifying those compounds that bind or ~~modulates~~ modulate HPTPbeta as compounds useful for the treatment of an angiogenesis mediated disorder.

Appl. No. 10/634,027
Docket No. 9045M2
Amdt. dated 12 October 2006
Reply to Office Action mailed on 13 April 2006
Customer No. 27752

6. (New) A method according to Claim 2, wherein the 3D structure of the HPTPbeta catalytic domain is defined by the atomic coordinates of Figures 7-102.
7. (New) A method according to Claim 2, wherein the 3D structure of the HPTPbeta catalytic domain is defined by the atomic coordinates of Figures 103-201.
8. (New) A method according to Claim 2, wherein the 3D structure of the HPTPbeta catalytic domain is defined by the atomic coordinates of Figures 202-252.
9. (New) A method according to Claim 2, wherein the 3D structure of the HPTPbeta catalytic domain is defined by the atomic coordinates of Figures 253-304.